4.5 Review

Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease

期刊

HYPERTENSION RESEARCH
卷 45, 期 4, 页码 635-640

出版社

SPRINGERNATURE
DOI: 10.1038/s41440-021-00840-w

关键词

Uric acid; Xanthine oxidoreductase; Chronic kidney disease; Atherosclerotic cardiovascular disease

资金

  1. [19K09023]
  2. [19K08980]
  3. [18H02863]

向作者/读者索取更多资源

Hyperuricemia is caused by a combination of reduced excretion and overproduction of uric acid, with potential complications including gout, hypertension, CKD, and CVD. Mechanisms such as inflammasome activation and oxidative stress are proposed to contribute to renal damage and atherosclerosis in hyperuricemia, highlighting the need for further research on purine metabolism and treatment strategies.
Hyperuricemia is caused by reduced renal/extrarenal excretion and overproduction of uric acid. It is affected by genetic predisposition related to uric acid transporters and by visceral fat accumulation due to overnutrition. The typical symptomatic complication of hyperuricemia is gout caused by monosodium urate crystals. Accumulated evidence from epidemiological studies suggests that hyperuricemia is also a risk factor for hypertension, chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (CVD). However, it remains to be determined whether urate-lowering therapy for asymptomatic patients with hyperuricemia is effective in preventing CKD or CVD progression. This mini review focuses mainly on recent papers investigating the relationship between hyperuricemia and CKD or CVD and studies of urate-lowering therapy. Accumulated studies have proposed mechanisms of renal damage and atherosclerosis in hyperuricemia, including inflammasome activation, decreased nitric oxide bioavailability and oxidative stress induced by uric acid, urate crystals and xanthine oxidoreductase (XOR)-mediated reactive oxygen species. Since patients with hyperuricemia are a heterogeneous population with complex pathologies, it may be important to assess whether an outcome is the result of decreasing serum uric acid levels or an inhibitory effect on XOR. To clarify the impact of hyperuricemia on CKD and CVD progression, high-quality and detailed clinical and basic science studies of hyperuricemia and purine metabolism are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据